Patient derived organoids to model rare prostate cancer phenotypes
There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify ther...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-04495-z |
id |
doaj-6298c3191ca44642a1ee5adc286008a4 |
---|---|
record_format |
Article |
spelling |
doaj-6298c3191ca44642a1ee5adc286008a42021-05-11T09:52:05ZengNature Publishing GroupNature Communications2041-17232018-06-019111010.1038/s41467-018-04495-zPatient derived organoids to model rare prostate cancer phenotypesLoredana Puca0Rohan Bareja1Davide Prandi2Reid Shaw3Matteo Benelli4Wouter R. Karthaus5Judy Hess6Michael Sigouros7Adam Donoghue8Myriam Kossai9Dong Gao10Joanna Cyrta11Verena Sailer12Aram Vosoughi13Chantal Pauli14Yelena Churakova15Cynthia Cheung16Lesa Dayal Deonarine17Terra J. McNary18Rachele Rosati19Scott T. Tagawa20David M. Nanus21Juan Miguel Mosquera22Charles L. Sawyers23Yu Chen24Giorgio Inghirami25Rema A. Rao26Carla Grandori27Olivier Elemento28Andrea Sboner29Francesca Demichelis30Mark A. Rubin31Himisha Beltran32Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCenter for Integrative Biology, University of TrentoCure First and SEngine Precision MedicineCenter for Integrative Biology, University of TrentoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalMeyer Cancer Center, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCure First and SEngine Precision MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineMeyer Cancer Center, Weill Cornell MedicineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCure First and SEngine Precision MedicineMeyer Cancer Center, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineThere are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.https://doi.org/10.1038/s41467-018-04495-z |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran |
spellingShingle |
Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran Patient derived organoids to model rare prostate cancer phenotypes Nature Communications |
author_facet |
Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran |
author_sort |
Loredana Puca |
title |
Patient derived organoids to model rare prostate cancer phenotypes |
title_short |
Patient derived organoids to model rare prostate cancer phenotypes |
title_full |
Patient derived organoids to model rare prostate cancer phenotypes |
title_fullStr |
Patient derived organoids to model rare prostate cancer phenotypes |
title_full_unstemmed |
Patient derived organoids to model rare prostate cancer phenotypes |
title_sort |
patient derived organoids to model rare prostate cancer phenotypes |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2018-06-01 |
description |
There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations. |
url |
https://doi.org/10.1038/s41467-018-04495-z |
work_keys_str_mv |
AT loredanapuca patientderivedorganoidstomodelrareprostatecancerphenotypes AT rohanbareja patientderivedorganoidstomodelrareprostatecancerphenotypes AT davideprandi patientderivedorganoidstomodelrareprostatecancerphenotypes AT reidshaw patientderivedorganoidstomodelrareprostatecancerphenotypes AT matteobenelli patientderivedorganoidstomodelrareprostatecancerphenotypes AT wouterrkarthaus patientderivedorganoidstomodelrareprostatecancerphenotypes AT judyhess patientderivedorganoidstomodelrareprostatecancerphenotypes AT michaelsigouros patientderivedorganoidstomodelrareprostatecancerphenotypes AT adamdonoghue patientderivedorganoidstomodelrareprostatecancerphenotypes AT myriamkossai patientderivedorganoidstomodelrareprostatecancerphenotypes AT donggao patientderivedorganoidstomodelrareprostatecancerphenotypes AT joannacyrta patientderivedorganoidstomodelrareprostatecancerphenotypes AT verenasailer patientderivedorganoidstomodelrareprostatecancerphenotypes AT aramvosoughi patientderivedorganoidstomodelrareprostatecancerphenotypes AT chantalpauli patientderivedorganoidstomodelrareprostatecancerphenotypes AT yelenachurakova patientderivedorganoidstomodelrareprostatecancerphenotypes AT cynthiacheung patientderivedorganoidstomodelrareprostatecancerphenotypes AT lesadayaldeonarine patientderivedorganoidstomodelrareprostatecancerphenotypes AT terrajmcnary patientderivedorganoidstomodelrareprostatecancerphenotypes AT rachelerosati patientderivedorganoidstomodelrareprostatecancerphenotypes AT scottttagawa patientderivedorganoidstomodelrareprostatecancerphenotypes AT davidmnanus patientderivedorganoidstomodelrareprostatecancerphenotypes AT juanmiguelmosquera patientderivedorganoidstomodelrareprostatecancerphenotypes AT charleslsawyers patientderivedorganoidstomodelrareprostatecancerphenotypes AT yuchen patientderivedorganoidstomodelrareprostatecancerphenotypes AT giorgioinghirami patientderivedorganoidstomodelrareprostatecancerphenotypes AT remaarao patientderivedorganoidstomodelrareprostatecancerphenotypes AT carlagrandori patientderivedorganoidstomodelrareprostatecancerphenotypes AT olivierelemento patientderivedorganoidstomodelrareprostatecancerphenotypes AT andreasboner patientderivedorganoidstomodelrareprostatecancerphenotypes AT francescademichelis patientderivedorganoidstomodelrareprostatecancerphenotypes AT markarubin patientderivedorganoidstomodelrareprostatecancerphenotypes AT himishabeltran patientderivedorganoidstomodelrareprostatecancerphenotypes |
_version_ |
1721449055614140416 |